Abstract
Pain is a highly unpleasant and aversive human emotion. While it is elicited from stimulation of peripheral receptors via the spinothalamic tract to the thalamus in the brain, “top-down”: modulation from the cortex originating in social cues, self-confidence and such factors are also important in pain experience and behavior. The most potent pain medications are the opiates that stimulate several types of opiate receptor in the thalamus and elsewhere. The endogenous ligands of these receptors, enkephalins, are important neurotransmitters that are chemically short peptides. Opiates are highly effective in acute pain but come with a high potential for tolerance and addiction and are rarely indicated in chronic pain. Treatment of opiate addiction may involve maintenance with a partial agonist such as methadone or buprenorphine to substitute for abused opiates while blocking use of nonprescribed additional opiates. Opiate abuse side effects include overdose coma and death due to respiratory depression, and naloxone or naltrexone opiate antagonists able to reverse overdose should be available to first responders as well as to psychiatrists.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246–55.
Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778–90.
McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468–79.
Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, et al. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiatry. 2021;78(7):767–77.
Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154–63.
Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357–68.
Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A. Trends in use and misuse of opioids in The Netherlands: a retrospective, multi-source database study. Lancet Public Health. 2019;4(10):e498–505.
D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.
Lott DC. Extended-release naltrexone: good but not a panacea. Lancet. 2018;391(10118):283–4.
Ortega R, Nozari A, Baker W, Surani S, Edwards M. Intranasal naloxone administration. N Engl J Med. 2021;384(12):e44.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.
Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) - pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med. 2019;380(19):1785–7.
Larance B, Dobbins T, Peacock A, Ali R, Bruno R, Lintzeris N, et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry. 2018;5(2):155–66.
Davis CS. The Purdue pharma opioid settlement - accountability, or just the cost of doing business? N Engl J Med. 2021;384(2):97–9.
Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–9.
Baker DW. History of the joint Commission’s pain standards: lessons for Today’s prescription opioid epidemic. JAMA. 2017;317(11):1117–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Belmaker, R.H., Lichtenberg, P. (2023). Pain Medication and Opiate Addiction. In: Psychopharmacology Reconsidered. Springer, Cham. https://doi.org/10.1007/978-3-031-40371-2_10
Download citation
DOI: https://doi.org/10.1007/978-3-031-40371-2_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-40370-5
Online ISBN: 978-3-031-40371-2
eBook Packages: MedicineMedicine (R0)